Applied Genetic Technologies Corporation Receives Second Grant from FDA for Clinical Study of Genetic Respiratory Disease  
9/16/2010 10:08:16 AM

GAINESVILLE, Fla.--(BUSINESS WIRE)--Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1 million from the Food and Drug Administration (FDA Orphan Drugs Program) to fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Alpha 1 Antitrypsin Deficiency (AAT), a genetic disease known to result in serious lung and/or liver disease. The clinical trial is being coordinated by AGTC at The University of Massachusetts by Dr. Terrence R. Flotte and Cincinnati Children’s Hospital Medical Center by Dr. Bruce C. Trapnell.